Drug Type Antibody fusion proteins |
Synonyms engineered ACE-2-IgG1-Fc fusion protein targeting SARS-CoV-2 receptor-binding domain protein(Eutilex/Chonbuk National University), EU-129, EU129 |
Target |
Mechanism SARS-CoV-2 S protein neutralization |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | KR | 01 Jul 2021 | |
Neoplasms | Preclinical | KR | - | |
Neoplasms | Preclinical | KR | - |